Michigan

Michigan’s practical policy picture is a split one: a handful of local deprioritisation actions at city level, but no statewide therapeutic access law, no state task force with implementation authority, and no psilocybin services market. For access researchers and journalists, that means local enforcement posture can differ from state criminal law and from actual healthcare availability.###

The key current statewide signal in the materials reviewed is HB 4686 in the 2025–2026 session. Its committee referral matters as a policy indicator, but it is still only a bill step, not an implementation event. Michigan therefore remains a state where local reform symbolism has outpaced statewide regulatory design.###

Michigan is one of the stronger research states in this group because the University of Michigan has created dedicated infrastructure. The Michigan Psychedelic Center says it launched in 2022 and describes work across education, research, therapy and community engagement, with university partners including the Center for Consciousness Science, the Chronic Pain & Fatigue Research Center, and the Michigan Institute for Clinical & Health Research.###

Its research page shows a broad portfolio ranging from foundational neurobiology to clinical implementation. That includes a 2025 publication on preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia, as well as preclinical psilocybin pain work and multiple ketamine publications. U‑M investigators have also publicly described a small proof-of-principle fibromyalgia psilocybin study and chronic-pain-focused psychedelic work.###

Ketamine research is more mature. The multi-site Bio‑K study included the University of Michigan and Pine Rest Christian Mental Health Services, and a separate chronic low back pain psilocybin study listed University of Michigan alongside Stanford and was still described as accepting new patients in Mar 2025.###

Because Michigan has no psychedelic services law, there is no state implementation stack for psilocybin or MDMA comparable to Oregon or Colorado. Operational reality instead sits in university IRB governance, federal research approvals, hospital policies, referral pathways and payment arrangements. The Michigan Psychedelic Center’s clinical FAQ is explicit that federally approved clinical trials are a lawful potential route for psychedelic therapy access.###

For ketamine and esketamine, implementation is institutional rather than legislative. U‑M’s clinic model uses psychiatrist referral, specialist oversight and structured payment procedures; the VA Ann Arbor model described by Michigan Medicine also signals that provider capacity and follow-on maintenance logistics matter as much as legal availability.###

The most important verified ecosystem anchor is the University of Michigan in Ann Arbor. The Michigan Psychedelic Center has a physical university footprint and a cross-disciplinary brief; U‑M Interventional Psychiatry and the U‑M Ketamine Clinic provide the clearest verified ordinary-care access infrastructure in-state.###

Pine Rest Christian Mental Health Services also appears in the Bio‑K ketamine research network, which makes Grand Rapids relevant on the depression side even without a classical psychedelic state pathway. Beyond that, the ecosystem is still far more research-and-health-system led than regulator-led.###

Over the next 12–24 months, Michigan’s likely near-term movement is still research and health-system activity, not a live state psilocybin services market. U‑M already has the institutional depth to keep producing pain and depression-related outputs, and that matters more for practical access than municipal resolutions do.###

Policy-wise, the main uncertainty is whether Michigan can move from local deprioritisation and symbolic reform into statewide design. Nothing in the reviewed materials shows an implementation authority, licensing track, or funded agency programme. Even if a state bill advances later, real access would still lag behind because rulemaking, training, facility standards and payer behaviour would all need to catch up.###